{"filing":{"accession_number":"0001493152-26-042791","cik":"0001757499","ticker":"SHPH","company_name":"Shuttle Pharmaceuticals Holdings, Inc.","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-09","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315226042791/form8-k.htm"},"events":[{"id":33721,"run_id":31021,"accession_number":"0001493152-26-042791","anchor_item_number":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses unregistered sales of equity securities under Item 3.02, specifically: (a) 2,869,595 shares of common stock from conversion of Series B-1 Preferred Stock, (b) 867,887 shares from conversion of Series B-2 Preferred Stock, (c) warrants to purchase approximately 927,114 shares at $10.30 per share, and (d) pre-funded warrants to purchase approximately 16,932,508 shares. These issuances were approved by stockholders at a special meeting on September 9, 2026, and rely on the Section 4(a)(2) exemption from Securities Act registration, indicating a private placement structure. The aggregate dilution from these securities is material to shareholders.","company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":37239,"accession_number":"0001493152-26-042791","item_number":null,"item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses unregistered sales of equity securities under Item 3.02, specifically: (a) 2,869,595 shares of common stock from conversion of Series B-1 Preferred Stock, (b) 867,887 shares from conversion of Series B-2 Preferred Stock, (c) warrants to purchase approximately 927,114 shares at $10.30 per share, and (d) pre-funded warrants to purchase approximately 16,932,508 shares. These issuances were approved by stockholders at a special meeting on September 9, 2026, and rely on the Section 4(a)(2) exemption from Securities Act registration, indicating a private placement structure. The aggregate dilution from these securities is material to shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-16T10:01:58.710617+00:00","company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","filing_date":"2026-09-15"}]}